Source link : https://www.newshealth.biz/health-news/precision-medicine-approach-shows-promise-for-anaplastic-thyroid-cancer/
Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. A trial of atezolizumab (Tecentriq) and mutation-selected targeted agents led to better overall survival (OS) as compared with historical results in anaplastic thyroid carcinoma (ATC), reaching a maximum of 43 months in BRAF-mutant tumors. On […]
Author : News Health
Publish date : 2024-10-25 21:31:25
Copyright for syndicated content belongs to the linked Source.
